Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Stock Markets May 11, 2022 19:11
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it’s Q1 report. Some of it’s shortfall was attributed by management to longer sales cycles in the insurer and employer space in addition to competitive concerns. But while TDOC is struggling to sign new insurers and employers, DarioHealth (NASDAQ: DRIO) seems to be thriving. In fact, the day after the TDOC report, an analyst covering DRIO, LifeSci Capital, came out with a note speculating that Dario Health is in fact taking business from Teladoc. This analyst reiterated a $31 price target. The stock is currently trading under $5. This represents a 6x potential return.

TDOC and DRIO have traded in lock-step for most of the last two years but since TDOC’s report, DRIO has dramatically outperformed, down just 5%, while TDOC is down a staggering 46%. This divergence in stock performance is a clue that many investors also feel that DRIO may be taking business from TDOC. One reason why risk assets drop in a rising interest rate environment is a higher cost of capital which growth companies need to reach profitability. In some cases, capital may not even be available. These dynamics cause investors to speculate about future dilutive offerings on bad terms which could hammer a stock price and keep it depressed for the long-term.

Due to this concern, StoryTrading recently interview Erez Raphael, the CEO of DRIO to press him on their cash runway and their plan to reach profitability. The interview with Erez left DRIO shareholders and members of the StoryTrading community satisfied that DRIO will avoid toxic dilutions prior to reaching profitability in early 2024. Not only does DRIO sport a cash balance of $80M, but the company is also pursuing non-dilutive lines of credit as a backstop and their new partner, Sanofi (EPA:SASY) (NASDAQ: SNY), seems likely to make an equity purchase in DRIO sometime this year on favorable terms. Incidentally, Dario met with Sanofi yesterday in New York City. Below is a picture of the two executive teams which was shared on LinkedIn by an executive of Sanofi.

This Thursday, investors will find out if Dario Health is on track to reach profitability in Q1 of 2024. Key will not only be revenue ramp but increased profit margins from the shift towards employer and insurer plans. Seven analysts cover Dario expecting an average of 6.7M in revenue in Q1 and a loss of $0.96 per share. If DRIO can meet or beat these numbers, it could further fuel the narrative that DRIO is taking market share away from TDOC. The StoryTrading community empowers individuals to make the best-informed trade and investment decisions through a holistic view of stocks based on the four pillars of Fundamentals, Catalysts, Sentiment, and Technicals. Analyzing all four pillars together can also help identify key inflection points. Can the catalyst of earnings this week turn investor sentiment up regarding the long-term fundamentals of DRIO? We will find out this Thursday when the Q1 report is revealed.

Disclaimer: The Author has a LONG position in DRIO

© 2022 Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Related Articles

UK to reduce Heathrow Airport landing fees
UK to reduce Heathrow Airport landing fees By Reuters - Jun 28, 2022

LONDON (Reuters) - London's Heathrow Airport will be forced to lower the landing fees it charges airlines over the next four years after Britain's aviation regulator responded to...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
Sign up with Email